Estimation of the Impact of Meningococcal Serogroup C Universal Vaccination in Italy and Suggestions for the Multicomponent Serogroup B Vaccine Introduction

Figure 3

Prevented fraction of IMD cases ≤18 years of age and vaccination coverage against meningococcus C in the Puglia region, within 2001–2013, by vaccine efficacy (VE [27]). (a) Estimated for VC of 57.3% among subjects ≤18 years of age, assuming VE of 83–100%. (b) Estimated VC among subjects ≤18 years of age for of 31.3%, assuming VE of 83–100%.

(a)

(b)